SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Integrative Cancer Therapies
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Lis, C. G.
Right arrow Articles by Hrushesky, W. J M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lis, C. G.
Right arrow Articles by Hrushesky, W. J M
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Cancer
*Cancer Chemotherapy
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Circadian Timing in Cancer Treatment: The Biological Foundation for an Integrative Approach

Christopher G. Lis, MPH

Vice President for Research, Cancer Treatment Centers of America, Midwestern Regional Medical Center, 2520 Elisha Ave. Zion, IL 60099. christopher.lis@mrmc-ctca.com

James F. Grutsch, PhD

Patricia Wood, MD, PhD

Mark You, MD, PhD

Ivan Rich, PhD

William J M Hrushesky, MD

Despite the many innovations that have occurred in cancer treatment, the age-specific mortality for most adult tumors has remained stable during the past 30 years. There have been clinically significant improvements in the outcomes of young and middle-aged patients, yet the vast majority of cancer patients are more than 50 years of age, among whom we observe few improvements in clinical outcomes. Clearly, many of today's cytotoxic agents have been shown to be effective in-vitro and in animal model systems; however, few have proved efficacious in dramatically improving survival outcomes in adult cancer. There is now increasing evidence to suggest that the administration of cytotoxic agents, at the appropriate circadian phase, can significantly increase the therapeutic index of current cancer therapies.

Key Words: cancer • chronobiology • chronotherapy • circadian rhythms • survival outcomes

Integrative Cancer Therapies, Vol. 2, No. 2, 105-111 (2003)
DOI: 10.1177/1534735403002002002
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Cold Spring Harb Symp Quant BiolHome page
M. Hughes, L. DeHaro, S. R. Pulivarthy, J. Gu, K. Hayes, S. Panda, and J. B. Hogenesch
High-resolution Time Course Analysis of Gene Expression from Pituitary
Cold Spring Harb Symp Quant Biol, January 1, 2007; 72(0): 381 - 386.
[Abstract] [PDF]

Home page
 Infect. Immun.Home page
J. Liu, G. Mankani, X. Shi, M. Meyer, S. Cunningham-Runddles, X. Ma, and Z. S. Sun
The circadian clock period 2 gene regulates gamma interferon production of NK cells in host response to lipopolysaccharide-induced endotoxic shock.
Infect. Immun., August 1, 2006; 74(8): 4750 - 4756.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
K. I. Block
Timing is Everything
Integr Cancer Ther, June 1, 2003; 2(2): 103 - 104.
[PDF]


Advertisement